Mandate

Vinge advises Irisity in connection with a directed new share issue

November 14, 2019 Capital Markets and Public M&A

Vinge is advising Irisity in connection with a directed new share issue of 4,094,000 shares whereby Irisity acquires approximately SEK 35 million.

A subscription price of SEK 8.55 has been determined through an accelerated book building procedure and constitutes a discount of approximately 7.1 per cent in comparison with the closing price of Irisity shares on Nasdaq First North on 13 November 2019. The issue proceeds, which are expected to be sufficient for Irisity to acquire a positive cashflow, are intended to strengthen the company’s financial stability and also be used to expand the organisation within the fields of research, development, marketing, sales and service. The resolution adopted by the board of directors concerning the new share issue is conditional upon the approval thereof at an extraordinary general meeting.

 

Vinge’s team mainly consisted of Anders StridJohanna Hamrefält and Lina André.

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025